Recommended interval is monthly.
Conflicting results regarding benefit.
In a randomized trial in Russia, after 13 years the number of cancers in the BSE group vs the non-BSE were the same, and no difference in mortality was seen, and no difference in the size or stage of breast cancer was seen (Semiglazov VF).
In a randomized control study in Shangai no differences were seen after 10-11 years in the BSE group compared to a control group in size, stage or mortality (Thomas DB).
In trials comparing BSE to no BSE more biopsies for benign lesions are performed.
BSE not advocated by most breast screening task forces, but recommendations are that women should be familiar with their breasts and report changes promptly to their health care providers.